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 Summary 
INTRODUCTION
 Spot and morning sputum samples are used in the diagnosis of Pulmonary Tuberculosis 
(TB). There are no guidelines currently for a choice of two sputum samples to be used in determining 
optimal performance of a diagnostic tool. Performance has been determined using one of the four 
approaches of choice of sputum samples in different studies with varying results.  
 The choices include; 
 (a)  Final diagnosis based on both spot and morning sample results, whereby the  
  patient is the unit of analysis (point-of-care) [1,3] 
 (b) Spot sample results 
 (c) Morning sample results  [1]
 (d)  Pooled results of spot and morning samples [3]
OBJECTIVE
 Whereby the sample is the unit of analysis (laboratory based) respectively, this study was 
to determine the appropriate choice of sputum sample(s) for optimal performance of TB diagnostic 
tools in Kenya.
METHODOLOGY
 A cross-sectional study was conducted between February 2013 and October 2016 in 
nine selected public health, facilities in Kenya.  People presumed to have TB aged 18 years and 
above visiting the facilities and eligible for the study were enrolled after consenting. Spot and 
early morning samples were collected over two consecutive days. Samples were analysed using 
Ziehl Neelsen (ZN), Light Emitting Diode-Fluorescent Microscopy (LED-FM).LED-FM and 
GeneXpert. Lowenstein Jensen LJ Culture was used as the gold standard. TB Positivity, Sensitivity 
and Specificity were determined using IBM-SPSS statistical software.
RESULTS
 There was significantly high TB identification with LJ culture, using final diagnosis based 
on both spot and morning sample results compared to separate samples. There was significantly 
higher incremental detection benefit with GeneXpert than with ZN and FM microscopy. However, 
there was no significant difference in sensitivities and specificities within the four approaches for 
choice of sputum sample used.
CONCLUSION 
 The findings provide evidence on the need to develop guidelines on choice of sputum 
samples to be used for accurate TB detection and validation of TB diagnostic tools.
[Afr. J. Health Sci. 2019 32(4) : 59 - 65]
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Introduction 
 A crucial impediment to global tuberculosis 
control is lack of accurate, rapid diagnostic test for 
detection of patients with active TB. Spot and morning 
sputum samples are used in the diagnosis of pulmonary 
tuberculosis (TB). Currently, there are no guidelines for 
standard choice of which sputum samples should be used 
in determining optimal performance of a diagnostic 
tool.
 A new, rapid diagnostic method, (Cepheid) 
Xpert MTB/RIF Assay (GeneXpert), is an automated 
sample preparation and real-time PCR instrument, 
which has shown to have good potential as an alternative 
to current reference standard sputum microscopy and 
Culture.
  Performance of GeneXpert has been determined 
using either of the four approaches of choice of sputum 
samples in different studies with varying results (Table 
1). The four choices are defined within each of the two 
units of analysis; 
 Patient as a unit of analysis - point-of-care.
The analysis performed by Rachow et al. 2011 used 
final results based on both spot and morning sample 
(Approach 1). They reported 88.4% (95%  CI =  78.4% 
to 94.9%) Sensitivity of GeneXpert among patients 
with a positive culture, and 99.0%  (95%   CI =  94.7% 
to 100.0%) Specificity in patients who had no TB. 
 Hence, using a similar approach, in 2014 
reported that GeneXpert achieved; 
 83.2% [77.9% - 89.4%] with specificity of
 95.0% [93.2% - 97.2%].
considering sputum sample as the unit of analysis - 
laboratory based. The study determined the diagnostic 
performance of GeneXpert using separate spot 
(Approach 2) and morning (Approach 3) samples [4].  
 There was reduced performance of GeneXpert 
with a Sensitivity of 57.0% [49.9%-64.2%] using spot 
samples, and 66.0% [59.9%-72.1%] using morning 
samples. There was no report of Specificity for 
the same. The study of 2014 carried out diagnostic 
performance using pooled results of spot and morning 
samples (Approach 4). They determined Sensitivity of 
GeneXpert to be 83.7% [76.6%-90.8%] and a Specificity 
of 87.9% [85.1%-90.7%] [3].
Publication Approach of choice of 
samples 
Sensitivity [95% CI] Specificity [95% CI]
Rachow et al. 2011 [1] Combined spot and morningsamples (Approach 1)
88.4% [78.4%-94.9%] 99.0%[ 94.7%-100.0%]
Theron et al. 2014 [2] Combined spot and morning samples [Approach 1]
83.2% [77.9%-89.4%] 95.0% [93.2%-97.2%]
Cavanaugh et al. 
2016 [3]
Spot samples [Approach 2] 57.0% [49.9%-64.2%] Not indicated
Morning samples [Approach 3] 66.0% [59.9%-72.1%] Not indicated





 Significant variation in sensitivity and 
specificity documented in the previous studies, 
informed the need to investigate the implication of 
choice of samples.  This study aims to determine the 
appropriate choice of sputum sample(s) for optimal 
performance of TB diagnostic tools.
Methodology
 A cross-sectional study conducted between 
February 2013 and October 2016 in nine selected public 
health, facilities in Kenya.  People presumed to have TB 
aged 18 years attending the facilities and eligible for the 
study were enrolled after consenting. 
Table 1: Previous Studies with Documented Sensitivity and / or Specificity of GeneXpert
ZN - Ziehl-Neelsen Microscopy; LED-FM - Led Emitted Diodides Fluorescent Microscopy; GeneXpert - Xpert  MTB/ RIF;     
CI - 95% Confidence Interval
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Table 2:   TB Positivity For Different Diagnostics Using Different Approaches Of Choice Of Samples
Approach of choice of samples Diagnostic tool n TB positivity (95% CI)
Approach 1: combined spot and  
                      morning samples
ZN 1683 16.6% [14.9%-18.4%]
LED-FM 1685 16.4% [14.7%-18.2%]
GeneXpert 786 23.4% [20.4%-26.4%]
LJ culture 1706 15.6% [13.9%-17.3%]
Approach 2: spot samples
ZN 1683 13.5% [11.9%-15.1%]
LED-FM 1685 14.2% [12.5%-15.9%]
GeneXpert 786 20.6% [17.6%-23.5%]
LJ culture 1706 12.5% [11.0%-14.1%]
Approach 3: morning samples
ZN 1683 13.5% [11.9%-15.2%]
LED-FM 1685 14.1% [ 12.5%-15.8%]
GeneXpert 786 21.0% [18.1%-23.9%]
LJ culture 1706 11.9% [10.4%-13.4%]
Approach 4: pooled spot and   
                      morning samples
ZN 3366 13.5% [12.4%-14.7%]
LED-FM 3370 14.2% [13.0%-15.4%]
GeneXpert 1572 20.8% [18.8%-22.8%]
  LJ Culture   3412   12.2% [11.1%-13.3%]
 Spot and early morning samples were collected 
over two consecutive days. A total of 3412 sputum 
samples were collected from 1706 people presumed to 
have TB. At KEMRI research laboratory, Nairobi, 3366 
sputum samples were analysed using Ziehl Neelsen (ZN), 
3370 with LED-FM and 1572 with GeneXpert while all 
the 3412 samples were processed for Lowenstein Jensen 
(LJ) Culture according to standard procedures. 
 All LJ positive cultures were subjected to an 
identification process using Immuno Chromomatogenic 
Assays (ICA) identification kit (BD MGIT TM TBc 
identification test) to confirm for MTB. A positive 
culture for MTB was used as a gold standard for 
positivity [2].  
 Data management and analysis was done 
using MySQL and IBM SPSS respectively. Percentage 
frequency was used for TB positivity for ZN, LED-FM 
GeneXpert and a positive culture for MTB.  
 Diagnostic test values (sensitivity, specificity) 
values were determined using culture for MTB as a gold 
standard. Sensitivity and specificity were generated 
using IBM-SPSS statistical software.
Results
 Table 2 presents TB positivity for different 
diagnostics using different approaches of choice of 
sputum samples. MTB detection with LJ Culture was 
significantly higher when both spot and morning sample 
results were used for final diagnosis (approach choice 1) 
than when results of either spot or morning samples were 
separately used (approach choices 2 and 3). Similarly, 
MTB detection with LJ Culture was significantly higher 
when both spot and morning sample results were used 
for final diagnosis (approach choice 1) than when results 
for pooled spot and morning samples (approach 4) were 
used.
 There was significantly higher incremental 
detection benefit with GeneXpert than with ZN and 
FM microscopy in all the four approaches of choice. 
Similarly, there was significantly higher incremental 
detection benefit with GeneXpert than LJ culture in all 
the four approaches of choice.
 Despite significant variation between specific 
diagnostic tool, there was no significant difference in 
sensitivities and specificities within specific diagnostic 
tool between the four approaches of choice.
Key: ZN - Ziehl-Neelsen Microscopy; LED-FM - Led Emitted Diodides Fluorescent Microscopy; GeneXpert - Xpert   MTB/ RIF;  
       CI - 95% Confidence Interval
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 Table 3 shows the reliability of results generated 
using homogeneous spot and morning samples for 
different TB diagnostics. With respect to the Kappa cut-
off references, the results from the spot sputum samples 
and those from the early morning sputum samples agree 
to a larger extent. The Kappa values for all diagnostic 
tools are >0.65 which implies there is good agreement 
in the results generated using spot and early morning 
sputum samples, the highest being GeneXpert (0.842 
[95% CI: 0.795-0.889]) and LED-FM (0.812 [95% 
CI: 0.7771-0.853]).
Table 3: Agreement Between Results For Spot and Morning Samples For Different TB Diagnostics
Diagnostic tool
Spot





Morning: Positive 175 53 228 6.2%[5.1%-7.4%] 0.733[0.684-0.782]
Morning: Negative 52 1403 1455
Total 227 1456 1683
LED-FM
Morning: Positive 200 38 238 4.6%[3.6%-5.6%] 0.812[0.771-0.853]
Morning: Negative 39 1408 1447
Total 239 1446 1685
GeneXpert
Morning: Positive 143 22 165 5.2%[3.7%-6.8%] 0.842[0.795-0.889]
Morning: Negative 19 602 621
Total 162 624 786
LJ Culture
Morning: Positive 151 52 203 6.7%[5.5%-7.9%] 0.686[0.633-0.739]
Morning: Negative 63 1440 1503
Total 214 1492 1706
Key: 95% CI - confidence interval; ZN - Ziehl-Neelsen microscopy; LED-FM - Led Emitted Diodide fluorescent microscopy;  
 GeneXpert - Xpert MTB/RIF ; n-Number
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 Table 4: presents sensitivity and specificity of 
TB diagnostic tools using different approaches of choice 
of samples. Sensitivity of GeneXpert was significantly 
higher and constant than for both ZN and LED-FM in 
all the approaches of choice. 
 However, specificity was significantly lower 
than that of ZN and LED-FM microscopy, respectively. 
There was no statistically significant difference 
in sensitivity and specificity of ZN and LED-FM 
microscopy in all the approaches of choice, respectively.
There was no significant difference in sensitivities and 
specificities between the four approaches of choice. 
 The 95% confidence interval for sensitivities 
and specificities were narrow for the pooled samples 
compared to those of combined and separate spot and 
morning samples. Pooling spot and morning samples 
for same number of patients, improves precision in 
estimation of performance of a diagnostic tool than 
using other analytical approaches.









ZN 265 69.4%[63.9%-75.0%] 1418 93.2%[91.9%-94.5%] 1683
LED-FM 266 71.1%[65.6%-76.5%] 1419 93.8%[92.5%-95.1%] 1685
GeneXpert 130 83.1%[76.6%-89.5%] 656 88.4%[86.0%-90.9%] 786
Approach 2:  
Spot samples
ZN 213 67.1%[60.8%-73.4%] 1470 94.3%[93.1%-95.5%] 1683
LED-FM 214 73.4%[67.4%-79.3%] 1471 94.4%[93.3%-95.6%] 1685
GeneXpert 101 88.1%[81.8%-94.4%] 685 89.3%[87.0%-91.7%] 786
Approach 3: 
Morning samples
ZN 202 63.4%[56.7%-70.0%] 1481 93.2%[92.0%-94.5%] 1683
LED-FM 203 69.5%[63.1%-75.8%] 1482 93.5%[92.2%-94.7%] 1685
GeneXpert 102 84.3%[77.3%-91.4%] 684 88.5%[86.1%-90.8%] 786
Approach 4: 
Pooled spot and 
morning samples 
ZN 415 65.3%[60.7%-69.9%] 2951 93.8%[92.9%-94.6%] 3366
LED-FM 417 71.5%[67.1%-75.8%] 2953 93.9%[93.1%-94.8%] 3370
GeneXpert 203 86.2%[81.5%-91.0%] 1369 88.9%[87.2%-90.6%] 1572
ZN - Ziehl-Neelsen microscopy; LED-FM - Led Emitted Diodide fluorescent microscopy; GeneXpert - Xpert 
MTB/ RIF; 95%  CI -Confidence interval
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Discussion
 Laboratory diagnosis of pulmonary TB 
involves analysis of spot and morning sputum samples 
mainly by microscopy and culture where available. 
Recent advances in molecular technology have added 
GeneXpert in TB diagnostic algorithm. 
 Patient management is optimized where final 
results of the combined spot and morning samples are 
used. The TB diagnostic tools have been validated using 
different approaches of choice of sputum samples. 
 The validation of TB diagnostic tools in 
2014 and 2016 was performed using specific spot and 
morning sputum samples, whereby the sample was the 
unit of analysis (Laboratory based) [2,4].
 The analysis by of 2016 was performed using 
separate spot and morning sputum samples while that 
of 2014 was performed using pooled spot and morning 
sputum samples. 
 Sensitivity of GeneXpert reported by in 2016 
for separate spot and morning samples was significantly 
lower than the one reported in 2014. Using similar 
approaches used in 2016 and 2014, the results from 
the studies, indicate no significant difference in the 
sensitivity of GeneXpert between the two approaches.
 The validation of TB diagnostic tools by Rachow 
et al. 2011 and Theron et al. 2014, were performed 
using final diagnosis results based on both spot and 
morning sputum sample, where the patient was the unit 
of analysis (point-of-care). Using similar approach, the 
results from the study was not significantly different 
from the previous one. [2,3]
 Generally, validation of TB diagnostics from 
our study show no significant difference in sensitivities 
and specificities within the four approaches of choice of 
sputum samples between specific TB diagnostic tool. 
 However, when pooled spot and morning 
samples approach was used, there was increased 
number of samples, yielding a narrow 95% confidence 
interval for sensitivities and specificities compared to 
the number of samples when combined and separate 
spot and morning sample approaches were used. 
 When results for pooled spot and morning 
samples for the same number of patients were used, there 
was improved precision in estimation of performance 
of a TB diagnostic tool compared to other analytical 
approaches.
 In addition, the results from this study 
has confirmed that, sensitivity of GeneXpert was 
significantly higher and specificity significantly lower 
than that of ZN and LED-FM, respectively, as observed 
in previous studies both in Kenya and elsewhere, 
regardless of the approach of choice [2] 
 Furthermore, the non-significant difference 
in sensitivity and specificity of ZN and LED-FM 
microscopy, respectively in all the approaches of choice, 
also confirm similar observations in the same previous 
studies [2]. 
 These results indicate that determination and 
performance of TB diagnostic tools is not limited by 
the approach of choice of sputum sample. Variation in 
performance reported in literature may be influenced 
by other factors, such as the level of technical skills to 
perform laboratory procedures, among others. 
 The Kappa values for all diagnostic tools 
indicated good expectations in the results generated 
using spot and early morning sputum samples. The 
highest being GeneXpert and LED-FM. The findings 
provide additional evidence that, validation of TB 
diagnostics is not limited choice of sputum sample.
 Clinical significance differences were observed 
between final diagnosis based on both spot and morning 
samples for LJ Culture results versus Other separate 
morning samples. This emphasizes the importance of 
using results based on both spot and morning samples 
when making a final diagnosis for patient management.
  This approach provides evidence of increased 
chance of ensuring that people presumed to have TB 
are promptly and correctly identified for adequate 
management. Patients identified to be positive using 
spot sample should immediately be put on treatment 
while those turning negative should bring the early 
morning sample the following day for confirmation. 
 This is the first time to document such findings 
and to our knowledge there is no policy that provides 
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guidelines on best approach for choice of sputum 
sample(s) to achieve optimal performance of a TB 
diagnostic tool as well as providing adequate diagnosis 
to people presumed to have TB.
Conclusion 
 Clinical significant differences observed 
between final diagnosis based on both spot and morning 
samples for LJ culture results versus other separate 
morning samples, provide additional evidence that 
informs policy makers on the dare need to emphasize 
on use of both spot and morning samples for high TB 
detection. 
 Patients identified to be positive using spot 
sample should be put on treatment while those turning 
negative should bring the early morning sample the 
following day for confirmation.
 Determination and performance of TB 
diagnostic tools is not limited by the choice of sputum 
sample. Variation in performance reported in literature 
may be influenced by other factors, such as the level of 
technical skills to perform laboratory procedures.
 These findings provide evidence on the need 
to develop guidelines on choice of sputum samples to 
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